ArticleClinical rheumatology2026
An epidemiological study estimating the burden of cancer risk in patients with Raynaud's phenomenon.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectiveRaynaud's phenomenon (RP) is a common vasospastic condition that may develop secondary to cancer and/or in association with systemic autoimmune rheumatic diseases (SARDs). We aimed to estimate the risk of cancer in RP without known SARDs, phenotypically akin to 'primary' RP.
methodsA cohort study using data from North American electronic healthcare organization records. RP was defined using ≥ 2 ICD (I73.0) codes, excluding SARDs. Comparators had ≥ 2 irritable bowel syndrome ICD (K58) codes: selected with similar epidemiology to RP, and without any known excess in cancer risk. Cohorts were stratified by age (< 45 and ≥ 45 years). Our primary outcome was any cancer event. Secondary outcomes were rates of specific cancers: head and neck, digestive, thorax, skin, breast, haematological, male/female genital. Risk of each outcome was compared using 1:1 propensity score-matched Cox proportional hazard models.
resultsAmong 34,582 (< 45 years) and 68,836 (≥ 45 years) matched pairs, the hazard ratio (HR) of any cancer was higher in RP: < 45 [1.11 (1.03, 1.19)] and ≥ 45 [1.08 (1.05, 1.11)]. Cancer-specific risks were calculated. RP was associated in both age groups with increased risk of thorax (HR 2.077 & 1.433), skin (HR 1.202 &1.213), and haematological (HR 1.647 & 1.338) cancers. RP was associated with decreased risk of digestive cancer (HR 0.686 & 0.894).
conclusionRP was associated with an increased risk of cancer, independent of age. We also describe varying cancer-specific risks. Future research is warranted to confirm and explore these novel observations, including potentially shared pathobiological mechanisms. Key Points • RP was associated with an overall increased risk of all cancers in younger (<45years) and older (≥45 years) individuals. • There was an increased risk of certain (e.g., thorax, skin, and haematological) cancers with RP. • A reduced risk of cancer was also noted for certain cancers, especially GI-related. • Future research should confirm and explore these observations, including the pathobiology underpinning potential cancer risk in RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.